Jiangsu Nhwa Pharmaceutical Co Ltd (SHE:002262) — Market Cap & Net Worth
Market Cap & Net Worth: Jiangsu Nhwa Pharmaceutical Co Ltd (002262)
Jiangsu Nhwa Pharmaceutical Co Ltd (SHE:002262) has a market capitalization of $2.84 Billion (CN¥19.43 Billion) as of June 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #5189 globally and #970 in its home market, demonstrating a -1.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Nhwa Pharmaceutical Co Ltd's stock price CN¥19.13 by its total outstanding shares 1015786583 (1.02 Billion). Review 002262 total liabilities to assess the company's total debt and financial obligations.
Jiangsu Nhwa Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Jiangsu Nhwa Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $1.96 Billion to $2.84 Billion (4.02% CAGR).
Jiangsu Nhwa Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Nhwa Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.61x
Jiangsu Nhwa Pharmaceutical Co Ltd's market cap is 0.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.39x
Jiangsu Nhwa Pharmaceutical Co Ltd's market cap is 3.39 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.83 Billion | $3.02 Billion | $309.74 Million | 0.61x | 5.90x |
| 2017 | $2.00 Billion | $3.39 Billion | $394.63 Million | 0.59x | 5.07x |
| 2018 | $1.27 Billion | $3.86 Billion | $524.81 Million | 0.33x | 2.42x |
| 2019 | $1.65 Billion | $4.15 Billion | $663.31 Million | 0.40x | 2.48x |
| 2020 | $2.27 Billion | $3.36 Billion | $728.82 Million | 0.68x | 3.12x |
| 2021 | $2.24 Billion | $3.94 Billion | $797.78 Million | 0.57x | 2.81x |
| 2022 | $3.58 Billion | $4.30 Billion | $900.71 Million | 0.83x | 3.97x |
| 2023 | $3.98 Billion | $5.04 Billion | $1.04 Billion | 0.79x | 3.84x |
| 2024 | $3.62 Billion | $5.70 Billion | $1.14 Billion | 0.64x | 3.17x |
| 2025 | $3.59 Billion | $5.91 Billion | $1.06 Billion | 0.61x | 3.39x |
Competitor Companies of 002262 by Market Capitalization
Companies near Jiangsu Nhwa Pharmaceutical Co Ltd in the global market cap rankings as of June 18, 2026.
Key companies related to Jiangsu Nhwa Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Jiangsu Nhwa Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jiangsu Nhwa Pharmaceutical Co Ltd's market cap moved from $1.96 Billion to $ 2.84 Billion, with a yearly change of 4.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.84 Billion | -20.72% |
| 2025 | CN¥3.59 Billion | -0.90% |
| 2024 | CN¥3.62 Billion | -9.03% |
| 2023 | CN¥3.98 Billion | +11.25% |
| 2022 | CN¥3.58 Billion | +59.41% |
| 2021 | CN¥2.24 Billion | -1.38% |
| 2020 | CN¥2.27 Billion | +38.18% |
| 2019 | CN¥1.65 Billion | +29.64% |
| 2018 | CN¥1.27 Billion | -36.55% |
| 2017 | CN¥2.00 Billion | +9.49% |
| 2016 | CN¥1.83 Billion | -6.96% |
| 2015 | CN¥1.96 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Jiangsu Nhwa Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.84 Billion USD |
| MoneyControl | $2.84 Billion USD |
| MarketWatch | $2.84 Billion USD |
| marketcap.company | $2.84 Billion USD |
| Reuters | $2.84 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin… Read more